Menu Search
Equities

PURE Biosciences Inc

PURE:PKC

PURE Biosciences Inc

Actions
Basic MaterialsChemicals
  • Price (USD)0.07
  • Today's Change-0.01 / -12.50%
  • Shares traded16.62k
  • 1 Year change-30.83%
  • Beta0.0385
Data delayed at least 15 minutes, as of Sep 19 2024 19:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year PURE Biosciences Inc's net income fell 13.46% from a loss of 3.49m to a larger loss of 3.96m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 213.71% to 222.96%.
Gross margin57.29%
Net profit margin-173.41%
Operating margin-168.15%
Return on assets-264.29%
Return on equity--
Return on investment-480.58%
More ▼

Cash flow in USDView more

In 2023, cash reserves at PURE Biosciences Inc fell by 2.30m. Cash Flow from Financing totalled 1.02m or 54.08% of revenues. In addition the company used 3.28m for operations while cash used for investing totalled 33.00k.
Cash flow per share-0.0313
Price/Cash flow per share--
Book value per share-0.0192
Tangible book value per share-0.0192
More ▼

Balance sheet in USDView more

PURE Biosciences Inc has a Debt to Total Capital ratio of 944.88%.
Current ratio1.30
Quick ratio1.19
Total debt/total equity--
Total debt/total capital9.45
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.